Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024

Company Overview - Vericel Corporation is a leader in advanced therapies for the sports medicine and severe burn care markets, combining innovations in biology with medical technologies to create a differentiated portfolio of cell therapies and specialty biologics [3] Product Portfolio - The company markets three main products in the United States: - MACI®: An autologous cellularized scaffold product for repairing full-thickness cartilage defects in the knee [3] - Epicel®: A permanent skin replacement for patients with deep dermal or full-thickness burns covering 30% or more of total body surface area [3] - NexoBrid®: A biological orphan product for eschar removal in burn patients, for which Vericel holds exclusive North American rights [3] Upcoming Events - Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 1:05 p.m. ET [1]